Indian J Pharm Close
 

Figure 4: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)- mediated intracellular accumulation of doxorubicin. The left showed intracellular doxorubicin fluorescence intensity. *Represents significant difference in MFI of doxorubicin between K562 cells and K562/DOX cells untreated and treated with verapamil (P < 0.01). **Represents significant difference in MFI of doxorubicin between K562/DOX cells treated with DMAG and those treated with verapamil (P < 0.01). The right shows VTIHCS600 High-Contents scanning images of intracellular doxorubicin accumulation. (a) K562 cells; (b) K562/DOX cells; (c) K562/ DOX cells treated with 1.0 μM of DMAG; (d) K562/DOX treated with 1.0 μM of verapamil, ×40

Figure 4: 5,5'-dimethoxylariciresinol-4'-O-β-D-glucoside (DMAG)- mediated intracellular accumulation of doxorubicin. The left showed intracellular doxorubicin fluorescence intensity. *Represents significant difference in MFI of doxorubicin between K562 cells and K562/DOX cells untreated and treated with verapamil (P < 0.01). **Represents significant difference in MFI of doxorubicin between K562/DOX cells treated with DMAG and those treated with verapamil (P < 0.01). The right shows VTIHCS600 High-Contents scanning images of intracellular doxorubicin accumulation. (a) K562 cells; (b) K562/DOX cells; (c) K562/ DOX cells treated with 1.0 μM of DMAG; (d) K562/DOX treated with 1.0 μM of verapamil, ×40